Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
23 authors.
Alison M SchramDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6070-2413
John J ParkMacquarie Medical School, Macquarie University, Sydney, NSW, Australia.ORCID 0000-0001-9290-8179
Antoine ItalianoDepartment of Medical Oncology, Institut Bergonié, Bordeaux, France.
Shigehisa KitanoDepartment of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID 0000-0002-4041-8298
Ye GuoDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-1813-9815
Jin LiMedical Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0003-0099-874X
Philippe L BedardDivision of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.ORCID 0000-0002-6771-2999
Cedric van MarckeDepartment of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Brussels, Belgium.ORCID 0000-0003-3454-0630
Ryo KoDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.ORCID 0000-0002-2551-3529
Lukas LungerGlobal Clinical Development ONCO, Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany.
Daniel M KlotzGlobal Clinical Development ONCO, Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany.
Jo HussainClinical Development Operations, Boehringer Ingelheim Ltd, Bracknell, Berkshire, UK.
Daniela MaierGlobal Biostatistics & Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
Damijan ErzenGlobal Clinical Development ONCO, Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany.ORCID 0000-0003-1205-4244
David PlanchardDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif, France.ORCID 0000-0002-1565-8310
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or · full record | OpenQuestion